Puma Biotechnology Inc - Company Profile
Powered by 
All the sales intelligence you need on Puma Biotechnology Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Puma Biotechnology Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Puma Biotechnology Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Puma Biotechnology Inc (Puma Biotechnology) is a biopharmaceutical company. It focuses on developing and commercializing novel therapeutics for the treatment of cancer. The company's product portfolio consists of Nerlynx (neratinib) tablets, a prescription medicine used alone to treat early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and cancer that has spread to other parts of the body (metastatic) in adults. Its product pipeline also consists of Alisertib, a selective, small-molecule inhibitor of aurora kinase A used in the treatment of non-small cell lung cancer and breast cancer. The company manufactures, supplies, stores, and distributes its products through third-party contractors. The company operates subsidiaries in the UK and the Netherlands. Puma is headquartered in Los Angeles, California, the US.
Headquarters
United States of America
Address
Suite 1700, 10880 Wilshire Boulevard, Los Angeles, California, 90024
Website
www.pumabiotechnology.com
Telephone
1 424 2486500
No of Employees
179
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PBYI (NASD)
Revenue (2024)
$228.4M
-0.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
2.8%
(2024 vs 2023)
Market Cap*
$449.6M
Net Profit Margin (2024)
XYZ
3.7%
(2024 vs 2023)
* As of and is in US$
Puma Biotechnology Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Nerlynx (Neratinib) Tablets: Breast Cancer | Nerlynx |
| Pipeline | |
| Neratinib: Tyrosine Kinase Inhibitor | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Puma Biotechnology Inc | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Los Angeles | Indianapolis | Rahway | New York City | North Chicago |
| State/Province | California | Indiana | New Jersey | New York | Illinois |
| No. of Employees | 179 | 50,605 | 75,000 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alan H. Auerbach | Chief Executive Officer; President; Chairman | Executive Board | 2011 | 56 |
| Maximo F. Nougues | Chief Financial Officer | Senior Management | 2018 | 57 |
| Douglas Hunt | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer | Senior Management | 2024 | 61 |
| Gordon Esplin | Chief Accounting Officer | Senior Management | 2021 | - |
| Heather J. Blaber | Senior Vice President - Marketing | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer